Category Archives: Global News Feed

FLORHAM PARK, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced that it entered into a Pre-Paid Advance Agreement (the “Agreement”) with YA II PN, LTD (“Yorkville”), an affiliate of Yorkville Advisors Global, LP.

View post:
Celularity Enters Into $150 Million Pre-Paid Advance Agreement with Yorkville

1 Change at constant exchange rates and scope corresponds to the organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the exchange rate used is the one from the previous financial year), and excluding change in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year.

Read more:
Virbac: increase in operating income in the first half of 2022 reflecting the dynamism of our business

SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced publication of peer-reviewed data detailing the discovery and preclinical profiling of antibodies from the Sorrento G-MAB™ library with neutralizing activity against SARS-CoV-2 in vitro and in vivo in Scientific Reports, a Nature portfolio journal. The full publication is available at:

Go here to read the rest:
Sorrento Announces the Publication in the Nature Journal Scientific Reports the Details of the Discovery of SARS-CoV-2 Neutralizing Antibodies from...

Industry luminary honored with PharmaVoice’s highest distinction, joining elite group of most inspiring leaders in the life sciences industry Industry luminary honored with PharmaVoice’s highest distinction, joining elite group of most inspiring leaders in the life sciences industry

Excerpt from:
Parexel’s Peyton Howell Awarded Prestigious PharmaVoice Red Jacket

Dr. Hamed has over 20 years of anti-infective experience and has spearheaded the global development and approval of multiple anti-infective products Dr. Hamed has over 20 years of anti-infective experience and has spearheaded the global development and approval of multiple anti-infective products

Follow this link:
Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

SAN FRANCISCO and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan, will participate in the Piper Sandler Heartland Summit as part of the panel “Healthcare Politics: FDA Proposals from Optimus, to ORBIS to RTOR and CONFIRM – How Might These Proposals Impact Oncology Drug Development and Implications?” on Thursday, September 22, 2022 at 11:30 a.m. C.T.

Continued here:
Kinnate Biopharma Inc. to Participate in the 2022 Piper Sandler Heartland Summit

Announced a $130 million registered direct offering and concurrent private placement priced at-the-market

See the rest here:
Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress

John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, Joins as a Strategic Advisor John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, Joins as a Strategic Advisor

More:
Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors

-- Combined Company to Trade on Nasdaq Under Ticker “SYRS” ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock --CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME’s special meeting, TYME’s stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the “Merger Agreement”), pursuant to which a direct, wholly owned subsidiary of Syros will merge with and into TYME, with TYME surviving as a wholly owned subsidiary of Syros (the “Merger”). At Syros’ special meeting, Syros’ stockholders also voted in favor of all proposals, including the proposal to approve the issuance of shares of Syros’ common stock to holders of TYME’s common stock in connection with the Merger and to certain of Syros’ investors in connection with a concurrent private investment in public equity (“PIPE”) financing.

Read more from the original source:
Syros and Tyme Technologies Announce Stockholder Approval of Merger

WOBURN, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the International Symposium on Biopolymers (“ISBP”) 2022 Conference. The event is taking place September 12 through September 16, 2022 in Sion, Switzerland.

Link:
Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present on Advancements in Producing PHA Bioplastic in Camelina at the ISBP 2022...